Bluejay Diagnostics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Indranil Dey
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 360 Massachusetts Avenue Acton MA United States of America 01720
- IPO Date
- Nov 10, 2021
- CIK
- 0001704287
- Website
- bluejaydx.com
- Similar Companies
- Business
- Bluejay Diagnostics, Inc. operates as a medical technology enterprise dedicated to advancing patient care through expedited, near-patient diagnostic solutions across the United States. The company is progressing its core Symphony platform, an innovative system featuring a fluorescence immuno-analyzer designed for efficient blood sample processing, biomarker separation, and immunoassay preparation leveraging non-contact centrifugal force. This platform utilizes specialized Symphony Cartridges, which integrate necessary reagents and components. Presently, Bluejay Diagnostics' primary focus lies on its Symphony IL-6 test, a leading candidate for sepsis triage and monitoring disease progression, aiming to deliver results in approximately 20-24 minutes. This critical sepsis test is currently undergoing a pivotal SYMON-II clinical trial, with patient enrollment approximately 50% complete. The company anticipates completing sample testing by late 2026 and targeting a 510(k) submission to the FDA in 2027, with potential approval by the third quarter of 2028, contingent on securing additional funding. Beyond sepsis, Bluejay also offers the ALLEREYE diagnostic test, an FDA-cleared point-of-care device for diagnosing allergic conjunctivitis. Further development is underway for additional tests leveraging the Symphony platform, including biomarkers like high-sensitivity troponin I/T for myocardial injury and N-terminal pro-B-type natriuretic peptide (NT-proBNP) for cardiac heart failure. Strategic collaborations are vital to the company's operations, including an amended licensing and supply arrangement with Toray Industries, Inc. for manufacturing key protein detection chip components, ensuring supply for clinical studies. Additionally, an expanded partnership with SanyoSeiko Co., Ltd. provides comprehensive manufacturing support for the Symphony analyzer and cartridges, advancing commercialization efforts. Bluejay Diagnostics, Inc. was established in 2015 and maintains its corporate headquarters in Acton, Massachusetts. The company executed a 1-for-50 reverse stock split effective November 18, 2024.
What's Going On With Bluejay Diagnostics Shares On Wednesday?
Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
Critical Contrast: Bluejay Diagnostics (NASDAQ:BJDX) & STERIS (NYSE:STE)
Reviewing Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Bluejay Diagnostics (NASDAQ:BJDX)
Bluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX)
Bluejay Announces Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
NorthStrive Fund II LP Issues Open Letter to the Board and Shareholders of Bluejay Diagnostics
Bluejay Diagnostics Announces All Prefunded Warrants Now Exercised
Bluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026
Bluejay Diagnostics (NASDAQ:BJDX) Trading 0.1% Higher – What’s Next?
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production
CVRx (NASDAQ:CVRX) versus Bluejay Diagnostics (NASDAQ:BJDX) Critical Comparison
Bluejay Diagnostics (NASDAQ:BJDX) Shares Down 6.2% – Time to Sell?
Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform
Bluejay Diagnostics Provides Second Quarter Business and Corporate Update